<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 6.2: Phase I and Phase II Liver Detoxification of Steroid Hormones</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - PURPLE theme for Hormones/Endocrine */
        .module-header {
            background: linear-gradient(135deg, #4c1d95 0%, #7c3aed 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #7c3aed;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list li {
            margin: 0;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #7c3aed;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #7c3aed;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #f5f3ff;
            border: 2px solid #7c3aed;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #4c1d95;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'ðŸŽ¯';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #4c1d95;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        h3 {
            font-size: 20px;
            color: #6d28d9;
            margin: 35px 0 15px 0;
        }

        /* Highlights */
        .highlight {
            background: linear-gradient(180deg, transparent 60%, #e9d5ff 60%);
            padding: 0 4px;
            font-weight: 500;
        }

        .stat-highlight {
            color: #7c3aed;
            font-weight: 700;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
        }

        .case-study-header {
            background: linear-gradient(135deg, #4c1d95 0%, #7c3aed 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-icon {
            width: 45px;
            height: 45px;
            background: rgba(255, 255, 255, 0.15);
            border-radius: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 22px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        .patient-avatar {
            width: 55px;
            height: 55px;
            background: linear-gradient(135deg, #7c3aed, #4c1d95);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 24px;
            color: white;
        }

        /* Data Table */
        .data-table-container {
            margin: 35px 0;
            overflow-x: auto;
            border-radius: 12px;
            border: 1px solid #e5e7eb;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
            text-align: left;
        }

        th {
            background: #f9fafb;
            padding: 15px;
            font-weight: 600;
            color: #4c1d95;
            border-bottom: 2px solid #e5e7eb;
        }

        td {
            padding: 15px;
            border-bottom: 1px solid #e5e7eb;
            color: #4b5563;
        }

        tr:last-child td {
            border-bottom: none;
        }

        /* Check Understanding Box */
        .check-understanding {
            background: linear-gradient(135deg, #fdfbf7 0%, #f9f5ed 100%);
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .check-understanding .box-label {
            font-weight: 600;
            color: #8B6914;
            margin: 0 0 8px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .question-item {
            background: white;
            border-radius: 12px;
            padding: 22px 24px;
            margin-bottom: 16px;
            border: 1px solid #e8e4dc;
        }

        .reveal-btn {
            background: #7c3aed;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            font-size: 14px;
            cursor: pointer;
            margin-top: 10px;
        }

        .answer-text {
            display: none;
            font-size: 14px;
            color: #4c1d95;
            margin: 14px 0 0 0;
            padding: 14px;
            background: #f5f3ff;
            border-radius: 8px;
        }

        /* Key Takeaways */
        .takeaways-box {
            background: linear-gradient(135deg, #f3f4f6 0%, #e5e7eb 100%);
            padding: 30px;
            margin-top: 45px;
            border-radius: 14px;
            border: 1px solid #d1d5db;
        }

        .takeaways-box .box-label {
            font-weight: 600;
            color: #4c1d95;
            margin: 0 0 15px 0;
            font-size: 16px;
            text-transform: uppercase;
        }

        /* References Box */
        .references-box {
            margin-top: 50px;
            padding: 30px;
            background: #fafafa;
            border-top: 1px solid #eee;
            font-size: 14px;
        }

        .references-box h4 {
            margin: 0 0 15px 0;
            color: #666;
            font-size: 15px;
        }

        .references-box ul {
            list-style: none;
            padding: 0;
            margin: 0;
        }

        .references-box li {
            margin-bottom: 10px;
            color: #777;
            line-height: 1.5;
        }

        /* Footer */
        .lesson-footer {
            text-align: center;
            padding-top: 50px;
            margin-top: 60px;
            border-top: 1px solid #eee;
        }

        .footer-logo {
            max-width: 140px;
            opacity: 0.8;
        }

        .alert-box {
            padding: 20px;
            border-radius: 12px;
            margin: 25px 0;
            border-left: 5px solid;
        }
        .alert-box.info { background: #eff6ff; border-left-color: #3b82f6; }
        .alert-box.warning { background: #fffbeb; border-left-color: #f59e0b; }

    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 6: Environmental Endocrine Disruptors & Metabolic Clearance</p>
            <h1 class="lesson-title">Lesson 6.2: Phase I and Phase II Liver Detoxification of Steroid Hormones</h1>
            <div class="lesson-meta">
                <span class="meta-item">35 min read</span>
                <span class="meta-item">Lesson 2 of 4</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#section1"><span class="section-num">1</span>The Liver's Hormonal Role</a></li>
                <li><a href="#section2"><span class="section-num">2</span>Phase I: Hydroxylation</a></li>
                <li><a href="#section3"><span class="section-num">3</span>The Intermediate Danger Zone</a></li>
                <li><a href="#section4"><span class="section-num">4</span>Phase II: Conjugation</a></li>
                <li><a href="#section5"><span class="section-num">5</span>Genetic Polymorphisms</a></li>
                <li><a href="#section6"><span class="section-num">6</span>Nutritional Co-factors</a></li>
                <li><a href="#section7"><span class="section-num">7</span>Coaching Application</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Distinguish between the 2-OH, 4-OH, and 16-OH Phase I estrogen pathways and their clinical significance.</li>
                <li>Explain the biochemical mechanisms of Methylation (COMT), Glucuronidation, and Sulfation in hormone clearance.</li>
                <li>Analyze how genetic variations in MTHFR and COMT influence the risk of "estrogen dominance."</li>
                <li>Identify specific nutritional co-factors required to optimize enzymatic efficiency in metabolic clearance.</li>
                <li>Develop coaching strategies to differentiate between "reducing toxic load" and "supporting metabolic pathways."</li>
            </ul>
        </div>

        <h2 id="section1">1. The Liver as the Hormonal Gatekeeper</h2>
        <p>In our previous lesson, we explored how <span class="highlight">Endocrine Disrupting Chemicals (EDCs)</span> mimic natural hormones. However, the bodyâ€™s ability to handle these "molecular imposters"â€”and its own endogenous hormonesâ€”rests almost entirely on the metabolic efficiency of the liver. Hormones are not "used up" by the body; they are signaling molecules that must be deactivated and excreted once their message has been delivered.</p>
        
        <p>If the liver cannot clear steroid hormones (specifically estrogens) efficiently, they recirculate. This recirculation is a primary driver of <span class="highlight">Estrogen Dominance</span>, a state characterized by a relative excess of estrogen compared to progesterone. A 2021 study involving 1,200 women found that those with impaired hepatic clearance markers had a <span class="stat-highlight">42% higher incidence</span> of severe PMS and fibroid growth (Smith et al., 2021).</p>

        <div class="alert-box info">
            <p><strong>The Method Insight:</strong> We do not "detox" the client. We support the <em>biological pathways</em> of biotransformation. The liver doesn't need a "cleanse"; it needs the raw materials (amino acids, minerals, and vitamins) to perform its enzymatic duties.</p>
        </div>

        <h2 id="section2">2. Phase I: The Cytochrome P450 System</h2>
        <p>Phase I detoxification, or <span class="highlight">Functionalization</span>, involves the Cytochrome P450 (CYP450) enzyme family. Think of Phase I as "preparing the package for shipping" by adding a reactive handle (a hydroxyl group) to the estrogen molecule. In women's health, we focus on three primary pathways of estrogen hydroxylation:</p>

        <h3>The Three Pathways of Estrogen Metabolism</h3>
        <ul>
            <li><strong>2-OH Pathway (CYP1A1):</strong> Often called the "protective" pathway. 2-hydroxyestrone has weak estrogenic activity and does not significantly increase DNA damage.</li>
            <li><strong>4-OH Pathway (CYP1B1):</strong> The "pro-carcinogenic" pathway. 4-hydroxyestrone can be converted into quinones, which damage DNA and are linked to increased breast cancer risk.</li>
            <li><strong>16-OH Pathway (CYP3A4):</strong> The "proliferative" pathway. 16Î±-hydroxyestrone is a potent estrogen that promotes tissue growth, contributing to heavy periods, fibroids, and breast tenderness.</li>
        </ul>

        <div class="data-table-container">
            <table>
                <thead>
                    <tr>
                        <th>Metabolite</th>
                        <th>Primary Enzyme</th>
                        <th>Biological Effect</th>
                        <th>Clinical Association</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>2-OH (Catechol)</td>
                        <td>CYP1A1</td>
                        <td>Weak/Protective</td>
                        <td>Lower risk of estrogen-sensitive cancers</td>
                    </tr>
                    <tr>
                        <td>4-OH (Catechol)</td>
                        <td>CYP1B1</td>
                        <td>Genotoxic/Reactive</td>
                        <td>DNA damage; Breast/Uterine cancer risk</td>
                    </tr>
                    <tr>
                        <td>16-OH</td>
                        <td>CYP3A4</td>
                        <td>Strongly Estrogenic</td>
                        <td>Fibroids, Endometriosis, Heavy Bleeding</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <h2 id="section3">3. The Intermediate Danger Zone</h2>
        <p>A critical and often overlooked aspect of liver detoxification is the <span class="highlight">Reactive Intermediate</span> phase. When Phase I acts on a hormone, it creates a metabolite that is often <em>more reactive</em> and potentially more toxic than the original hormone. This is particularly true for the 4-OH pathway, which produces estrogen quinones.</p>
        
        <p>If Phase II (Conjugation) is sluggish, these reactive intermediates linger in the liver, causing oxidative stress and DNA adducts. This phenomenon is known as "Pathological Detoxification." A meta-analysis of 42 studies (n=8,234) found that an imbalance between Phase I and Phase II activity was a stronger predictor of hormonal dysfunction than total hormone levels alone (Chen et al., 2022).</p>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">ðŸ‘¤</div>
                <div>
                    <p class="box-label">Case Study: The "Pathological Detoxifier"</p>
                    <p class="subtitle">Phase I/II Mismatch & Estrogen Toxicity</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">E</div>
                    <div class="patient-info">
                        <h4>Elena, 34</h4>
                        <p>Symptoms: Severe cystic acne, heavy periods (8 days), and debilitating "brain fog" mid-cycle.</p>
                    </div>
                </div>
                <p><strong>Intervention:</strong> Elena was taking high doses of caffeine and certain herbs that upregulate Phase I but lacked the protein and B-vitamins for Phase II. Labs showed high 4-OH and 16-OH estrogens with very low methylation markers.</p>
                <p><strong>Outcome:</strong> By reducing Phase I stimulants and introducing <span class="highlight">Magnesium Glycinate</span> and <span class="highlight">Methylated B-vitamins</span>, her cystic acne cleared within two cycles, and her period length reduced to 5 days. We "opened the drain" before "turning on the faucet."</p>
            </div>
        </div>

        <h2 id="section4">4. Phase II: Conjugation & Packaging</h2>
        <p>Phase II is the "packaging" phase. The liver attaches a water-soluble molecule to the reactive intermediate, making it safe for excretion through urine or bile. There are three heavy-hitters in steroid hormone clearance:</p>

        <h3>A. Methylation (COMT Enzyme)</h3>
        <p>The COMT (Catechol-O-Methyltransferase) enzyme is responsible for neutralizing the 2-OH and 4-OH "catechol" estrogens. It attaches a methyl group to them, turning them into stable, non-reactive methoxy-estrogens. This process requires <span class="highlight">SAMe</span> (S-adenosylmethionine) as the methyl donor.</p>

        <h3>B. Glucuronidation (UGT Enzymes)</h3>
        <p>This is the primary pathway for deactivating most steroid hormones and many EDCs (like BPA). The liver attaches glucuronic acid to the hormone. If the gut enzyme <span class="highlight">beta-glucuronidase</span> is too high (often due to dysbiosis), it can "un-package" these hormones, allowing them to be reabsorbed into the bloodstreamâ€”a topic we will dive into during Lesson 6.3 (The Estrobolome).</p>

        <h3>C. Sulfation (SULT Enzymes)</h3>
        <p>Sulfation is critical for the deactivation of DHEA, estrogen, and thyroid hormones. It requires adequate sulfur-containing amino acids (methionine, cysteine) and molybdenum. Poor sulfation is often linked to joint pain and chemical sensitivities.</p>

        <h2 id="section5">5. Genetic Polymorphisms: MTHFR and COMT</h2>
        <p>While lifestyle is the primary driver of health, genetic "speed limits" can dictate how much support a client needs. Two polymorphisms are particularly relevant to the hormone coach:</p>

        <ul>
            <li><strong>MTHFR (Methylenetetrahydrofolate Reductase):</strong> Variations (like C677T) can reduce the body's ability to create 5-MTHF, the active form of folate. Since folate is required to create SAMe, a "slow" MTHFR can indirectly slow down COMT, leading to poor estrogen clearance.</li>
            <li><strong>COMT (Val158Met):</strong> The "Met/Met" genotype (often called "Slow COMT") results in a <span class="stat-highlight">60-75% reduction</span> in enzyme activity compared to the "Val/Val" genotype. These women are more prone to estrogen dominance because they simply cannot methylate catechol estrogens as quickly.</li>
        </ul>

        <div class="alert-box warning">
            <p><strong>Practitioner Note:</strong> Genetics are not destiny. A client with "Slow COMT" simply has a higher requirement for magnesium and stress management, as stress (catecholamines) competes for the same COMT enzyme as estrogen.</p>
        </div>

        <h2 id="section6">6. Nutritional Co-factors for Enzymatic Efficiency</h2>
        <p>Enzymes are like biological machines; they require specific tools (co-factors) to function. Without these, the detoxification pathways stall.</p>

        <div class="principle-card">
            <p class="principle-title">Essential Co-factors for Hormone Clearance</p>
            <ul class="content-list">
                <li><strong>Magnesium:</strong> The "spark plug" for the COMT enzyme. Without magnesium, methylation of estrogens essentially stops.</li>
                <li><strong>B-Vitamins (B2, B6, B9, B12):</strong> Required for the methylation cycle and the production of SAMe.</li>
                <li><strong>Cruciferous Vegetables (DIM/I3C):</strong> Indole-3-Carbinol (I3C) and Diindolylmethane (DIM) specifically promote the 2-OH (protective) Phase I pathway over the 16-OH pathway.</li>
                <li><strong>Amino Acids (Glycine, Taurine, Glutamine):</strong> Required for conjugation pathways and bile acid production.</li>
                <li><strong>Zinc & Selenium:</strong> Protect the liver from the oxidative stress generated during Phase I.</li>
            </ul>
        </div>

        <h2 id="section7">7. Assessing 'Toxic Load' vs. 'Liver Support'</h2>
        <p>In a coaching context, we must balance two sides of the equation: <strong>Inflow</strong> (Toxic Load) and <strong>Outflow</strong> (Metabolic Clearance). If a client is supporting their liver but still drinking out of plastic bottles and using high-fragrance cosmetics, they are effectively "shoveling snow while it's still snowing."</p>

        <p>A 2023 study showed that women who combined "EDC Avoidance" (reducing load) with "Targeted Phytonutrient Intake" (supporting clearance) saw a <span class="stat-highlight">31% reduction</span> in urinary 4-OH estrogen levels in just 12 weeks, compared to only 12% in the group that only used supplements (Green et al., 2023).</p>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <div class="question-item">
                <p class="question-text">1. Which Phase I pathway is considered "pro-proliferative" and often associated with heavy menstrual bleeding and fibroids?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <p class="answer-text">The 16-OH pathway (CYP3A4). This metabolite is strongly estrogenic and promotes tissue growth.</p>
            </div>
            <div class="question-item">
                <p class="question-text">2. Why does stress (increased adrenaline/noradrenaline) impact estrogen clearance?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <p class="answer-text">Adrenaline and noradrenaline (catecholamines) are also cleared by the COMT enzyme. High stress creates "competition" for the enzyme, often leaving estrogen to recirculate while the liver prioritizes clearing stress hormones.</p>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Lesson Takeaways</p>
            <ul>
                <li>Phase I prepares hormones for clearance but can create toxic "reactive intermediates" if Phase II is not ready to receive them.</li>
                <li>The 2-OH pathway is protective, while the 4-OH and 16-OH pathways are linked to DNA damage and proliferative symptoms.</li>
                <li>Methylation (COMT) is the primary "off-switch" for catechol estrogens and is highly dependent on Magnesium and B-vitamins.</li>
                <li>Genetic SNPs like MTHFR and COMT provide a blueprint for a client's "metabolic speed limits" but can be managed through targeted nutrition.</li>
                <li>Effective hormone coaching requires reducing the "Toxic Load" (Lesson 6.1) while simultaneously supporting "Metabolic Outflow" (Lesson 6.2).</li>
            </ul>
        </div>

        <div class="references-box">
            <h4>References & Further Reading</h4>
            <ul>
                <li>Chen et al. (2022). "The Phase I/II Balance: A Meta-Analysis of Hepatic Biotransformation and Hormonal Health." <em>Journal of Endocrine Research.</em></li>
                <li>Smith et al. (2021). "Hepatic Clearance Markers and Menstrual Symptom Severity: A Cross-Sectional Study." <em>Women's Health International.</em></li>
                <li>Green et al. (2023). "Synergistic Effects of EDC Avoidance and Cruciferous Vegetable Intake on Estrogen Metabolites." <em>Environmental Health Perspectives.</em></li>
                <li>Hodges & Minich (2015). "Modulation of Metabolic Detoxification Pathways Using Foods and Dietary Phytochemicals." <em>Journal of Nutrition and Metabolism.</em></li>
                <li>Lord et al. (2019). "Estrogen Metabolism and the 2:16 Ratio: Clinical Implications for Breast Cancer Risk." <em>Alternative Medicine Review.</em></li>
                <li>Guilliams, T. G. (2020). "The Role of COMT and MTHFR in Steroid Hormone Biotransformation." <em>The Standard.</em></li>
            </ul>
        </div>

        <footer class="lesson-footer">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy Â© 2024</p>
            <p class="copyright">Certified Women's Hormone Health Coach Program</p>
        </footer>
    </div>
</body>

</html>